Neoplasms

All Conditions

Symptoms and General Pathology

Mouth and Tooth Diseases

Ear, Nose, and Throat Diseases

Rare Diseases

Carcinoma

Recurrence

Head and Neck Neoplasms

Nasopharyngeal Carcinoma

Mouth Neoplasms

Oral Cancer

Laryngeal Cancer

Hypopharyngeal Cancer

Sinus Cancer

Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Patients with Advanced Head and Neck Cancer Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).

The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.

Antineoplaston therapy (Atengenal + Astugenal)

Stanislaw R. Burzynski, MD, PhD

Current therapies for advanced Head and Neck Cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of advanced Head and Neck Cancer.

PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with advanced Head and Neck Cancer.

Advanced Head and Neck Cancer patients receive gradually escalating doses of intravenous Antineoplaston therapy (Atengenal + Astugenal) until the maximum tolerated dose is reached. Treatment continues up to12 months in the absence of disease progression or unacceptable toxicity.

OBJECTIVES:

* To determine the efficacy of Antineoplaston therapy in patients with advanced Head and Neck Cancer, as measured by an objective response to therapy (complete response, partial response or stable disease).
* To determine the safety and tolerance of Antineoplaston therapy in patients with advanced Head and Neck Cancer.
* To determine objective response, tumor size is measured utilizing MRI scans, which are performed every 8 weeks for the first two years, every 3 months for the third and fourth years, every 6 months for the 5th and sixth years, and annually thereafter.

Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer

Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Head and Neck

Burzynski Research Institute

Respiratory Tract (Lung and Bronchial) Diseases

Musculoskeletal Diseases

Behaviors and Mental Disorders

Sarcoma

Paranasal Sinus Neoplasms

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Nose Neoplasms

Otorhinolaryngologic Neoplasms

Nose Diseases

Respiratory Tract Diseases

Paranasal Sinus Diseases

Respiratory Tract Neoplasms

Otorhinolaryngologic Diseases

Quality of Life

Soft Tissue Sarcoma

patients with soft tissue sarcoma accept endoscopic surgery

endoscopic surgery

hongmeng Yu, doctor

Kai Xue, doctor

Soft tissue sarcoma (STS) refers to a group of malignant tumors derived from non-epithelial extraosseous tissues, mainly from the mesoderm, partly from the neuroectoderm, including muscle, fat, fibrous tissue, blood vessels and peripheral nerves . STS is divided into 12 major categories based on tissue origin. According to different morphologies and biological behaviors, there are more than 50 subtypes. The most common subtypes include: undifferentiated pleomorphic sarcoma (UPS), liposarcoma (LPS), leiomyosarcoma (LMS), synovial sarcoma ( SS). The most common soft tissue sarcoma in children and adolescents is rhabdomyosarcoma (RMS). Soft tissue sarcoma is a group of highly heterogeneous tumors, which are characterized by local invasiveness, invasive or destructive growth, local recurrence and distant metastasis.

The pathological features of STS that occur in the nasal cavity and sinuses are similar to other parts of the body. However, because it can affect important structures such as the orbit, optic nerve, skull base bone, dura mater, cranial nerve and even brain tissue, the diseased site is deep, the anatomical structure is complex, the treatment is difficult, the range of surgical resection is limited, and the surgical margin Negative is difficult to guarantee, and related treatments may have obvious complications, which affect the survival and prognosis of patients.

Surgical treatment is the most important and most likely effective treatment for STS. With the development of endoscopic skull base anatomy and surgical techniques, the safety and effectiveness of endoscopic sinus surgery for the treatment of nasal cavity and sinus tumors have been fully confirmed, and it has become the main surgical method for nasal cavity and sinus STS. This is also the theoretical and practical basis for the feasibility of this research.

The study intends to conduct a single-arm, prospective, observational study of endoscopic sinus surgery for the treatment of soft tissue sarcoma of the nasal cavity and paranasal sinuses to explore the therapeutic effect and complications of endoscopic surgery for the treatment of soft tissue sarcoma of the nasal cavity and paranasal sinuses, and explore its relationship with chemotherapy and radiotherapy. The model of comprehensive treatment between.

The study intends to conduct a single-arm, prospective, observational study of endoscopic sinus surgery for the treatment of soft tissue sarcoma of the nasal cavity and paranasal sinuses to explore the therapeutic effect and complications of endoscopic surgery for the treatment of soft tissue sarcoma of the nasal cavity and paranasal sinuses, and explore its relationship with chemotherapy and radiotherapy. The model of comprehensive treatment between.This study is divided into a screening period, a treatment period, and a follow-up period. All subjects need to sign an informed consent form before screening, perform relevant blood tests, imaging examinations, and compare the inclusion and exclusion criteria to select suitable patients to enter the treatment period. The follow-up period is 5 years.

tumor，para-carcinoma tissue，venous blood

Endoscopic Surgery in the Treatment of Soft Tissue Sarcoma in Nasal and Paranasal Sinus

Prospective Observational Single Arm Study of Endoscopic Surgery in the Treatment of Soft Tissue Sarcoma in Nasal and Paranasal Sinus

From the day of enrollment to death for any reason

The time from enrollment to local recurrence or death for any reason

The Chinese version of EORTC QLQ C30 questionnaire (V3.0)

Eye & ENT Hospital of Fudan University

Laryngeal Diseases

Oropharyngeal Neoplasms

Laryngeal Neoplasms

Nasopharyngeal Neoplasms

Mouth Diseases

Stomatognathic Diseases

Pharyngeal Neoplasms

Pharyngeal Diseases

Nasopharyngeal Diseases

Eligible patients will receive IMRT of 60-70Gy in 30-35 once-daily fractions with or without concurrent chemotherapy according to the current standard of care.

ART involved modification of the radiation treatment plan during treatment course to account for temporal variations in anatomy due to changes in tumor volume and/or patients' weight loss.

Adaptive Radiotherapy

C. Jillian Tsai, MD

The purpose of this study is to demonstrate that adaptive radiotherapy (ART) in head and neck cancer patients are comparable to historical controls in head and neck patients undergoing standard intensity-modulated radiation therapy (IMRT) without ART.

Adaptive Radiotherapy for Head and Neck Cancer

A Prospective Non-Inferiority Trial of the Use of Adaptive Radiotherapy for Head and Neck Cancer Undergoing Radiation Therapy

This is assessed by imaging studies and/or physical exams at follow- up visits. This will include a diagnostic FDG PET/CT scan. CT and/or MRI of the primary site and neck will also be recommended. Patients will be classified as locoregional recurrence-free as long as there is no evidence of locoregional recurrence of disease by clinical evaluation, CT, MRI, and/or PET-CT according to the standard of care. For patients achieving complete response of disease, no further imaging study is necessary.

Memorial Sloan Kettering Cancer Center

Camrelizumab was administrated with 200mg each time, every three weeks for a total of 11 cycles since the first day of induction chemotherapy.

camrelizumab

Fei Han

Pu-Yun OuYang

Fei Han, M.D.

Pu-Yun OuYang, M.D.

Patients with locoregional cancer of nasal cavity and paranasal sinuses are candidate for this study. All the eligible patients receive three cycles of induction chemotherapy (docetaxel 60mg/m2+cisplatin 60mg/m2+5-FU2.5g/m2,civ48h, q3w) followed by concurrent two cycles of cisplatin (80mg/m2,q3w) with curative intensity modulated radiotherapy. Besides, camrelizumab (200mg) is administrated every three weeks for a total of 11 cycles since the first day of induction chemotherapy. We aim to evaluate the three years failure free survival of these patients by the combination of camrelizumab with curative radiotherapy and chemotherapy.

Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses

Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses: a Phase II Multicenter Study

time from the randomization to the first treatment failure or death

Sun Yat-sen University

professor

Digestive System Diseases

Blood and Lymph Conditions

Skin and Connective Tissue Diseases

Gland and Hormone Related Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Heart and Blood Diseases

Immune System Diseases

Diseases and Abnormalities at or Before Birth

Nervous System Diseases

Nutritional and Metabolic Diseases

Syndrome

Esophageal Neoplasms

Leukemia

Cholangiocarcinoma

Breast Neoplasms

Pancreatic Neoplasms

Melanoma

Skin Neoplasms

Prostatic Neoplasms

Thyroid Neoplasms

Thyroid Diseases

Stomach Neoplasms

Carcinoma, Renal Cell

Lung Neoplasms

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Multiple Myeloma

Neoplasms, Plasma Cell

Adenomatous Polyposis Coli

Urinary Bladder Neoplasms

Vaginal Neoplasms

Gastrointestinal Stromal Tumors

Liver Neoplasms

Neuroendocrine Tumors

Thyroid Nodule

Mesothelioma

Mesothelioma, Malignant

Duodenal Neoplasms

Thymoma

Thymus Neoplasms

Central Nervous System Neoplasms

Testicular Neoplasms

Kidney Neoplasms

Anus Neoplasms

Nervous System Neoplasms

Endometrial Neoplasms

Salivary Gland Neoplasms

Gallbladder Neoplasms

Bile Duct Neoplasms

Urethral Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms, Hereditary Nonpolyposis

Hypopharyngeal Neoplasms

Intestinal Neoplasms

Penile Neoplasms

Ureteral Neoplasms

Peritoneal Neoplasms

Neoplasms, Unknown Primary

Lip Neoplasms

Paraproteinemias

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Male Urogenital Diseases

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms, Nerve Tissue

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Gastrointestinal Neoplasms

Digestive System Neoplasms

Endocrine Gland Neoplasms

Gastrointestinal Diseases

Pancreatic Diseases

Endocrine System Diseases

Genital Diseases, Female

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Gonadal Disorders

Rectal Neoplasms

Intestinal Diseases

Rectal Diseases

Urologic Neoplasms

Urologic Diseases

Colonic Diseases

Esophageal Diseases

Ken Cowan, MD

Michelle M Desler, MS

Jeannie Robbins

Noelle Beauchemin, MD

Sandy Allten, RN

Erik Harris, MD

Sandra Allten, RN,OCN,CCRP

Kellie Hyde

Luke Hazen

Joseph Meschi, MD

Amanda Baker, CCRP

Joseph T Meschi, MD

Neil Sharma, MD

Breck Hunnicutt, RN BSN CCRC

Betsy Glowinski

Anuj Agarwala, MD

Michael Zlomke, MD

Tammy Johnson, CBPN

Karrie Cheeseman, BSN, RN

Mukund Nadipuram, MD

Kelley Aldrich

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer	NCT00003489	Head and Neck C...	Antineoplaston ...	16 Years - 99 Years	Burzynski Research Institute
Endoscopic Surgery in the Treatment of Soft Tissue Sarcoma in Nasal and Paranasal Sinus	NCT05614375	Sarcoma,Soft Ti... Nasal Cavity Ca... Paranasal Sinus... Surgery	endoscopic surg...	-	Eye & ENT Hospital of Fudan University
Adaptive Radiotherapy for Head and Neck Cancer	NCT03096808	Head and Neck C... Paranasal Sinus... Oropharynx Canc... Oral Cavity Can... Nasopharynx Can... Larynx Cancer Hypopharynx Can...	Adaptive Radiot...	18 Years -	Memorial Sloan Kettering Cancer Center
Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer	NCT00003489	Head and Neck C...	Antineoplaston ...	16 Years - 99 Years	Burzynski Research Institute
Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses	NCT05114707	Nasal Cavity Ca... Paranasal Sinus... Camrelizumab Induction Chemo... Intensity Modul... Concurrent Chem...	camrelizumab	18 Years - 65 Years	Sun Yat-sen University
Integrated Cancer Repository for Cancer Research	NCT02012699	Pancreatic Canc... Thyroid Cancer Lung Cancer Esophageal Canc... Thymus Cancer Colon Cancer Rectal Cancer Gastrointestina... Anal Cancer Bile Duct Cance... Duodenal Cancer Gallbladder Can... Gastric Cancer Liver Cancer Small Intestine... Peritoneal Surf... Familial Adenom... Lynch Syndrome Bladder Cancer Kidney Cancer Penile Cancer Prostate Cancer Testicular Canc... Ureter Cancer Urethral Cancer Hypopharyngeal ... Laryngeal Cance... Lip Cancer Oral Cavity Can... Nasopharyngeal ... Oropharyngeal C... Paranasal Sinus... Nasal Cavity Ca... Salivary Gland ... Skin Cancer Central Nervous... Central Nervous... Mesothelioma Breast Cancer Leukemia Melanoma Sarcoma Unknown Primary... Multiple Myelom... Ovarian Cancer Endometrial Can... Vaginal Cancer Neuroendocrine ... Plasma Cell Dys... Healthy Control		19 Years - 110 Years	University of Nebraska

Spots Global Cancer Trial Database for paranasal sinus cancer